Condition: Central Diabetes Insipidus · Sponsor: University Hospital, Basel, Switzerland
The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.
This description comes directly from the study's public registry record.
Mirjam Christ-Crain, Prof. · +41 61 265 25 25 · Mirjam.Christ-Crain@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel | Basel, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06789705